Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) will present at two investor conferences in May 2026 via fireside chats: Bank of America Healthcare Conference in Las Vegas on May 12, 2026 at 9:20 a.m. PT and RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026 at 9:00 a.m. ET.

According to the company, live webcasts and archived replays will be available in the Investors > News and Events section at www.kymeratx.com.

News Market Reaction – KYMR

+4.29%

+4.29% Session close to close

In the May 6 session, KYMR gained 4.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines Kymera’s participation in two May healthcare investor conferences, provid...

Analysis

This announcement outlines Kymera’s participation in two May healthcare investor conferences, providing opportunities for management to discuss its oral degrader pipeline and recent developments with the investment community. In the past months, the company reported FDA Fast Track for KT-621, detailed Q1 2026 results, and shared new preclinical data for KT-579. Investors may focus on whether these conferences add incremental clarity on timelines, partnerships, or strategic priorities beyond what has already been disclosed.

Key Figures

Bank of America conference time: 9:20 a.m. PT RBC conference time: 9:00 a.m. ET

2 metrics

Bank of America conference time 9:20 a.m. PT Bank of America 2026 Healthcare Conference on May 12

RBC conference time 9:00 a.m. ET RBC Capital Markets 2026 Global Healthcare Conference on May 19

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Preclinical data update	Positive	-1.1%	Presented new preclinical IBD data for KT-579 showing reduced disease activity.
May 05	Leadership appointments	Neutral	-1.1%	Jeito Capital announced senior leadership hires with extensive life sciences experience.
Apr 30	Earnings and update	Neutral	-0.5%	Reported Q1 2026 results, strong cash position, Gilead milestone, and trial timelines.
Apr 23	Earnings date notice	Neutral	-1.8%	Announced timing and webcast details for the Q1 2026 results release.
Apr 13	Regulatory designation	Positive	+4.1%	Received U.S. FDA Fast Track designation for KT-621 in moderate to severe asthma.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows that clearly positive catalysts, such as FDA Fast Track, have coincided with upside moves, while several other operational or data updates have seen modest share price declines despite generally constructive content.

Recent Company History

Over the past month, Kymera has reported multiple developments across its pipeline and corporate calendar. On April 13, FDA Fast Track for KT-621 in asthma coincided with a 4.09% gain. Subsequent items included the Q1 2026 earnings release on April 30, an earnings-date notice on April 23, and new preclinical data for KT-579 on May 5, each followed by modest share price declines. Today’s conference-participation announcement fits into this cadence of frequent investor and scientific engagement updates.

Key Terms

oral small molecule degrader

1 terms

oral small molecule degrader medical

"a new class of oral small molecule degrader medicines for immunological diseases"

An oral small molecule degrader is a pill-form drug that binds to a specific disease-related protein and sends it to the cell’s natural disposal system so the protein is broken down and removed. For investors, these drugs represent a different way to tackle targets that were hard to block with traditional drugs, so successful clinical results can change a company’s prospects quickly—think of swapping a bandage for a vacuum that removes the root cause.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: 

• Bank of America 2026 Healthcare Conference in Las Vegas, NV on May 12 at 9:20 a.m. PT; and
• RBC Capital Markets 2026 Global Healthcare Conference in New York, NY on May 19 at 9:00 a.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events. 

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
mhenson@kymeratx.com
857-285-5300

FAQ

When will Kymera Therapeutics (KYMR) present at the Bank of America 2026 Healthcare Conference?

Kymera will present a fireside chat on May 12, 2026 at 9:20 a.m. PT. According to the company, the session will be webcast live and later archived on the Investors > News and Events page at www.kymeratx.com for replay.

What date and time is Kymera presenting at the RBC Capital Markets 2026 Global Healthcare Conference?

Kymera's fireside chat is scheduled for May 19, 2026 at 9:00 a.m. ET. According to the company, investors can watch the live webcast and access archived replays afterward on the company's Investors > News and Events website.

How can investors watch Kymera Therapeutics (KYMR) webcasts for the May 2026 conferences?

Investors can view live webcasts and archived replays on Kymera's website under Investors > News and Events. According to the company, both the May 12 and May 19 fireside chats will be available there for live viewing and later replay.

Will Kymera (KYMR) make replay recordings of the May 2026 conference presentations available?

Yes. According to the company, replays of the webcasts will be archived and available following the May 12 and May 19 events. Investors should check the Investors > News and Events section on www.kymeratx.com for posted replay links and timing.